Every lot published · search any lot number before you order

Retatrutide and Liver Fat: What the MASLD Substudy Measured

A randomized Phase 2a substudy evaluated participants with elevated liver fat. Its main measure was relative change in liver fat at 24 weeks, assessed within a selected group from the obesity study.

Retatrutide and Liver Fat: What the MASLD Substudy Measured. Liver fat measured in a defined subgroup. Liver-fat measure, 24 weeks, Relative change. GLP LIFE SCIENCES · RESEARCH BRIEF 47 Liver fat measured in a defined subgroup Safety and methods Liver-fat measure24 weeksRelative change
Liver fat measured in a defined subgroup. Illustration for this research brief.

Liver fat measured in a defined subgroup

In the 12 mg group, the paper reported an average relative reduction in liver fat of 82.4%, compared with a 0.3% increase in the placebo group. This is a liver-fat measure, separate from body-weight change.

How to interpret the evidence

The study population and imaging endpoint matter. These results do not establish outcomes such as reduced cirrhosis or long-term liver-related events.

This research summary focuses on a defined endpoint or safety observation. Its relevance depends on the study’s population and follow-up.

Sources